This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Boston Scientific (BSX) Faces Rising Costs, Competition
by Zacks Equity Research
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands
by Zacks Equity Research
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
Why You Should Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
Why You Should Retain Inari Medical (NARI) Stock for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Shockwave Medical's (SWAV) Reducer Receives Positive Results
by Zacks Equity Research
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
Do Options Traders Know Something About Cardinal Health (CAH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cardinal Health (CAH) stock based on the movements in the options market lately.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
by Zacks Equity Research
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
by Zacks Equity Research
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers
by Zacks Equity Research
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
Here's Why Cardinal Health (CAH) Fell More Than Broader Market
by Zacks Equity Research
Cardinal Health (CAH) concluded the recent trading session at $109.47, signifying a -0.41% move from its prior day's close.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Philips (PHG) Boosts Patient Monitoring With smartQare Deal
by Zacks Equity Research
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
BD's (BDX) Latest Product to Offer Wider Access to Researchers
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
by Zacks Equity Research
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
by Zacks Equity Research
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
Labcorp (LH) Extends MRD Clinical Research With New Launch
by Zacks Equity Research
Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
by Zacks Equity Research
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.